HanAll Biopharma and Daewoong Entered into Co-Development Agreement with NurrOn to Develop Novel Therapies for Parkinson’s Disease

Shots:

The companies collaborated to discover & develop novel therapies for patients with neurodegenerative diseases incl. Parkinson’s disease
The collaboration will combine companies’ expertise and resources in developing NurrOn’s ATH-399A & other compounds targeting Nurr1 for neurodegenerative disorders. The P-I trial of ATH-399A is expected to be initiated in 2023
The companies also continue to advance the therapy in other neurodegenerative diseases. HanAll’s HL161, an anti-FcRn Ab is being evaluated in P-II & P-III trials for autoimmune diseases incl. MG, TED, CIDP, and GD while HL036, a TNF-alpha inhibitor protein is being studied in the P-III trials in the US & China for dry eye disease

Ref: PR Newswire  | Image: Hanall

Related News:- Akebia Signs a License Agreement with Medice Arzneimittel Pütter GmbH&Co.KG to Commercialize Vafseo for Anemia Associated with CKD

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com